CAS: 1753-50-0; 2-Chloropyrimidine-5-Carbonitrile

相似化合物

374068-01-6 933702-55-7 856595-94-3

上下游产品

2-aminopyrimidine-5-carbonitrile ethyl 2-chloropyrimidine-5-carboxylate ethyl 2-oxo-1,2-dihydropyrimidine-5-carboxylate 2-bromopyrimidine-5-carboxylic acid 2-[4-(4-benzyl-phthalazin-1-yl)-piperazin-1-yl]-pyrimidine-5-carbonitrile [(3R,4S)-1-(5-cyanopyrimidin-2-yl)-4-(2,5-difluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester 2-but-3-ynyloxypyrimidine-5-carbonitrile N-methylbenzylamine hydr°Chloride

2-羟基嘧啶-5-羧酸乙酯置于n,N-二甲基甲酰胺 草酰氯,氨,水,三乙胺,三氟乙酸酐,Sodium Hydroxide,三氯氧磷体系中,用 四氢呋喃,1,4-二氧六环 用作溶剂,化学反应 9.33H,反应生成2-氯-5-氰基嘧啶
参考文献:Heteroaromatic Compounds As Inhibitors Of Stearoyl-Coenzyme A Delta-9 Desaturase
标题:Heteroaromatic Compounds As Inhibitors Of Stearoyl-Coenzyme A Delta-9 Desaturase
摘要:结构式i的杂环芳香化合物相对于其他已知的硬脂酰辅酶a去饱和酶(Scd1),是选择性抑制剂.本发明的化合物对于预防和治疗与异常脂质合成和代谢相关的疾病非常有用,包括心血管疾病,如动脉粥样硬化;肥胖;糖尿病;神经系统疾病;代谢综合征;胰岛素抵抗;和肝脂肪变性.

专利信息

专利号:WO-2023091726-A1
优先权日:2021-11-18
标题:Inhibitors of cyclin‑dependent kinase 12 (cdk12)
发明人：BENOIT GUILLAUME; CARULLI JOHN; CHEN FEI; CHUAQUI CLAUDIO; CIBLAT STEPHANE; COOPER ELLIOT; DAGENAIS ROBIN; HU SHANHU; KABRO ANZHELIKA; LAPLACA DEREK; MARINEAU JASON; MOEBIUS DAVID; MOON DIANE; SOLODININ ANDREI; WHITMORE KENNETH
权利人:SYROS PHARMACEUTICALS INC
摘要:The present invention provides chemical compounds that inhibit one or more families of kinases (e.g., serine/threonine kinases, including one or more of the families of CDK proteins, and in particular, CDK12). More specifically, the present invention provides CDK12 inhibitors, of formula (I), pharmaceutically acceptable salts and isotopically labeled derivatives thereof, pharmaceutical compositions containing the compounds/inhibitors, and methods of their synthesis and use in treating proliferative diseases (e.g., a bladder cancer, a breast cancer, Ewing's sarcoma, a gastric cancer, a gastrointestinal cancer, a hematologic cancer, a lung cancer (e.g., small cell lung cancer (SCLC)), an ovarian cancer (e.g., a high grade serous ovarian cancer), a pancreatic cancer (e.g., pancreatic ductal adenocarcinoma (PDAC)), a brain cancer (e.g., glioblastoma), or a prostate cancer), alone or in combination with a second therapeutic agent. The proliferative disease can be a cancer, benign neoplasm, or pathologic angiogenesis, and any of the therapeutic methods or uses described herein can include a step of diagnosing the patient's disease. In other embodiments of the invention, the compositions described herein (e.g., the compounds, pharmaceutical compositions, and kits containing them) are used for the treatment of myotonic dystrophy (type 1 or type 2).

专利号:US-2011152295-A1
优先权日:2008-09-08
标 题:Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
发明人：LECLERC JEAN-PHILIPPE; LI CHUN SING; RAMTOHUL YEEMAN K
权利人:LECLERC JEAN-PHILIPPE; LI CHUN SING; RAMTOHUL YEEMAN K
摘要:Heteroaromatic compounds of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.

专利号:CN-109666000-A
优先权日:2018-12-24
标 题 :A kind of cyclopropionil drug impurity and its synthesis method and application